401 related articles for article (PubMed ID: 14670976)
41. A role for histone deacetylase activity in HDAC1-mediated transcriptional repression.
Hassig CA; Tong JK; Fleischer TC; Owa T; Grable PG; Ayer DE; Schreiber SL
Proc Natl Acad Sci U S A; 1998 Mar; 95(7):3519-24. PubMed ID: 9520398
[TBL] [Abstract][Full Text] [Related]
42. Multiple histone deacetylases and the CREB-binding protein regulate pre-mRNA 3'-end processing.
Shimazu T; Horinouchi S; Yoshida M
J Biol Chem; 2007 Feb; 282(7):4470-4478. PubMed ID: 17172643
[TBL] [Abstract][Full Text] [Related]
43. Selective inhibitor of histone deacetylase 6 (tubastatin A) suppresses proliferation of hepatitis C virus replicon in culture of human hepatocytes.
Kozlov MV; Kleymenova AA; Konduktorov KA; Malikova AZ; Kochetkov SN
Biochemistry (Mosc); 2014 Jul; 79(7):637-42. PubMed ID: 25108326
[TBL] [Abstract][Full Text] [Related]
44. Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors.
Smil DV; Manku S; Chantigny YA; Leit S; Wahhab A; Yan TP; Fournel M; Maroun C; Li Z; Lemieux AM; Nicolescu A; Rahil J; Lefebvre S; Panetta A; Besterman JM; Déziel R
Bioorg Med Chem Lett; 2009 Feb; 19(3):688-92. PubMed ID: 19111466
[TBL] [Abstract][Full Text] [Related]
45. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma.
Marquard L; Gjerdrum LM; Christensen IJ; Jensen PB; Sehested M; Ralfkiaer E
Histopathology; 2008 Sep; 53(3):267-77. PubMed ID: 18671804
[TBL] [Abstract][Full Text] [Related]
46. Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs).
Schäfer S; Saunders L; Eliseeva E; Velena A; Jung M; Schwienhorst A; Strasser A; Dickmanns A; Ficner R; Schlimme S; Sippl W; Verdin E; Jung M
Bioorg Med Chem; 2008 Feb; 16(4):2011-33. PubMed ID: 18054239
[TBL] [Abstract][Full Text] [Related]
47. CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo.
Buggy JJ; Cao ZA; Bass KE; Verner E; Balasubramanian S; Liu L; Schultz BE; Young PR; Dalrymple SA
Mol Cancer Ther; 2006 May; 5(5):1309-17. PubMed ID: 16731764
[TBL] [Abstract][Full Text] [Related]
48. Isoform-selective HDAC1/6/8 inhibitors with an imidazo-ketopiperazine cap containing stereochemical diversity.
Lecointre B; Narozny R; Borrello MT; Senger J; Chakrabarti A; Jung M; Marek M; Romier C; Melesina J; Sippl W; Bischoff L; Ganesan A
Philos Trans R Soc Lond B Biol Sci; 2018 Jun; 373(1748):. PubMed ID: 29685969
[TBL] [Abstract][Full Text] [Related]
49. Design, synthesis, and biological evaluation of HDAC6 inhibitors targeting L1 loop and serine 531 residue.
Jha S; Kim JH; Kim M; Nguyen AH; Ali KH; Gupta SK; Park SY; Ha E; Seo YH
Eur J Med Chem; 2024 Feb; 265():116057. PubMed ID: 38142511
[TBL] [Abstract][Full Text] [Related]
50. Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate.
Sekhavat A; Sun JM; Davie JR
Biochem Cell Biol; 2007 Dec; 85(6):751-8. PubMed ID: 18059533
[TBL] [Abstract][Full Text] [Related]
51. Histone deacetylase 6 (HDAC6) is an independent deacetylase for alpha-tubulin.
Zhao Z; Xu H; Gong W
Protein Pept Lett; 2010 May; 17(5):555-8. PubMed ID: 19961433
[TBL] [Abstract][Full Text] [Related]
52. HDAC6 is a microtubule-associated deacetylase.
Hubbert C; Guardiola A; Shao R; Kawaguchi Y; Ito A; Nixon A; Yoshida M; Wang XF; Yao TP
Nature; 2002 May; 417(6887):455-8. PubMed ID: 12024216
[TBL] [Abstract][Full Text] [Related]
53. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally.
Zhang Y; Kwon S; Yamaguchi T; Cubizolles F; Rousseaux S; Kneissel M; Cao C; Li N; Cheng HL; Chua K; Lombard D; Mizeracki A; Matthias G; Alt FW; Khochbin S; Matthias P
Mol Cell Biol; 2008 Mar; 28(5):1688-701. PubMed ID: 18180281
[TBL] [Abstract][Full Text] [Related]
54. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
[TBL] [Abstract][Full Text] [Related]
55. CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo.
Cao ZA; Bass KE; Balasubramanian S; Liu L; Schultz B; Verner E; Dai Y; Molina RA; Davis JR; Misialek S; Sendzik M; Orr CJ; Leung L; Callan O; Young P; Dalrymple SA; Buggy JJ
Mol Cancer Ther; 2006 Jul; 5(7):1693-701. PubMed ID: 16891455
[TBL] [Abstract][Full Text] [Related]
56. Tubulin hyperacetylation is adaptive in cardiac proteotoxicity by promoting autophagy.
McLendon PM; Ferguson BS; Osinska H; Bhuiyan MS; James J; McKinsey TA; Robbins J
Proc Natl Acad Sci U S A; 2014 Dec; 111(48):E5178-86. PubMed ID: 25404307
[TBL] [Abstract][Full Text] [Related]
57. Tubulin acetylation promoting potency and absorption efficacy of deacetylase inhibitors.
Mangas-Sanjuan V; Oláh J; Gonzalez-Alvarez I; Lehotzky A; Tőkési N; Bermejo M; Ovádi J
Br J Pharmacol; 2015 Feb; 172(3):829-40. PubMed ID: 25257800
[TBL] [Abstract][Full Text] [Related]
58. IIp45 inhibits cell migration through inhibition of HDAC6.
Wu Y; Song SW; Sun J; Bruner JM; Fuller GN; Zhang W
J Biol Chem; 2010 Feb; 285(6):3554-3560. PubMed ID: 20008322
[TBL] [Abstract][Full Text] [Related]
59. Alcohol-induced alterations in hepatic microtubule dynamics can be explained by impaired histone deacetylase 6 function.
Shepard BD; Joseph RA; Kannarkat GT; Rutledge TM; Tuma DJ; Tuma PL
Hepatology; 2008 Nov; 48(5):1671-9. PubMed ID: 18697214
[TBL] [Abstract][Full Text] [Related]
60. Сlass II histone deacetylases in the post-stroke recovery period-expression, cellular, and subcellular localization-promising targets for neuroprotection.
Demyanenko S; Berezhnaya E; Neginskaya M; Rodkin S; Dzreyan V; Pitinova M
J Cell Biochem; 2019 Dec; 120(12):19590-19609. PubMed ID: 31264264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
